CP
ACET icon

Castleview Partners’s Adicet Bio ACET Stock Holding History

Castleview Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,994
Closed -$46.6K – 178
2024
Q4 		$46.6K Sell
2,994
-279
-9% -$5.26K 0.03% 347
2024
Q3 		$75.4K Buy
+3,273
New +$73.3K 0.04% 268

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Castleview Partners's ACET Position: Q1 2025 in Review

Castleview Partners sold out of Adicet Bio (ACET) in Q1 2025, closing a stake of 2,994 shares — an estimated $46.6K sold.

Castleview Partners first reported a position in ACET in Q3 2024 and held it in 2 quarters. The position peaked at $75.4K in Q3 2024. 56 funds tracked by Wall St. Rank hold ACET as of Q1 2025.

  • Castleview Partners reported no remaining Adicet Bio position as of Q1 2025 after selling out during the quarter.
  • Castleview Partners sold 2,994 Adicet Bio shares in Q1 2025, an estimated $46.6K.
  • Castleview Partners first reported a position in Adicet Bio in Q3 2024 and held it in 2 quarters.
  • Castleview Partners's Adicet Bio position peaked at $75.4K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.